News
Public · Published
ARCH Venture Fund XII Discloses Investment in City Therapeutics with 25.6% Stake
ARCH Venture Fund XII disclosed a 25.6% stake in City Therapeutics, holding 13,692,507 shares. On October 19, 2026, the fund bought 170,000 shares at $18 each from the IPO underwriters, adding to shares received when its preferred stock converted at the IPO.
Published:
Updated:
What happened
ARCH Venture Fund XII disclosed a 25.6% stake in City Therapeutics, holding 13,692,507 shares. On October 19, 2026, the fund bought 170,000 shares at $18 each from the IPO underwriters, adding to shares received when its preferred stock converted at the IPO.
Confirmed
Global impact / market context
A large stake held by a venture fund signals concentrated ownership in City Therapeutics after its IPO. Because the fund says it bought for investment purposes and has no plans to change the company, investors may see this as a passive hold rather than a push for control.
Analyst inference
The purchase from IPO underwriters came alongside shares converted from preferred stock, a common pattern when early backers keep exposure after a listing. That can reduce the free float available for trading, which means fewer shares on the market and potentially sharper price moves.
Analyst inference
What to watch
- The filing states the fund bought 170,000 shares at $18 each on October 19, 2026, which is a concrete price investors can compare with later trading in City Therapeutics stock. Confirmed
- Watch for any later filing where ARCH Venture Fund XII changes its stated intent or buys or sells more shares, since its current position is for investment purposes with no plans to affect the company. Proposed
- Because a 25.6% stake leaves a smaller free float, watch trading volume and price swings in City Therapeutics, which means how many shares change hands and how sharply the price moves. Analyst inference
Evidence
- Original source link unavailable